Imperagen Raises £5 Million to Revolutionize Enzyme Engineering with Quantum Physics and AI

Million to Revolutionize Enzyme Engineering with Quantum Physics and AI">

Imperagen, a biotech startup founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr.

Andy Almond, has announced a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company aims to transform enzyme engineering by making it faster, more efficient, and less costly than the traditional trial-and-error process. Imperagen's approach involves harnessing three core technologies to redefine enzyme engineering.

The company utilizes a quantum physics-based simulation to predict the behavior of enzyme variants on a computer, exploring millions of mutations. This information is then translated into custom AI models, trained on specific enzyme problems. To refine its AI models, Imperagen employs robots and automation to generate experimental data, which is fed back to the AI model in a process called closed-loop simulation.

Enzymes play a crucial role in various industries, particularly in pharmaceuticals, where they are essential for drug development. By accelerating enzyme engineering, startups like Imperagen can have a ripple effect, making processes like drug discovery faster and more efficient. Enzymes are also used in sectors such as food, biofuels, and agriculture, with experts looking to enzymes and surrounding AI technologies to make industrial production and manufacturing more sustainable.

The field of enzyme engineering is gaining traction, with companies like Biomatter, Cradle Bio, and Absci also working on innovative solutions. Imperagen has also announced that Guy Levy-Yurista will take on the role of CEO. Levy-Yurista notes that current enzyme engineering processes often fall short, with even AI-powered technologies struggling to scale industrially.

Imperagen aims to make enzyme development 'faster, more reliable, and more commercially accessible,' enabling companies to bring better bio-based products to market more efficiently. Levy-Yurista, with a background in AI, life sciences, and enterprise technology, will focus on building out Imperagen's new technologies, including a vertical AI infrastructure for biocatalysis, while scaling the startup's AI strategy, commercial models, and industrial partnerships. The company has raised £8.5 million ($11.42 million) in funding to date and will use the fresh capital to hire more AI specialists, invest in research and development, expand its experimental lab capabilities, and establish a go-to-market function within the next two years.